Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).

Abstract

BACKGROUND/AIM:

S-1, a 5-fluorouracil(5-FU) oral anti-cancer drug, has been traditionally used with a schedule of 4-week oral administration followed by 2-week rest for breast cancer treatment. We, herein, aimed to investigate the clinical efficacy and safety of a schedule of 2-week oral administration followed by 1-week rest for patients with metastatic breast cancer.

PATIENTS AND METHODS:

We enrolled patients with HER2-negative metastatic breast cancer who had not received prior chemotherapy. S-1 was administered consecutively for 2-weeks followed by a 1-week rest.

RESULTS:

Between September 1, 2013 and August 31, 2016, 32 patients were enrolled. The median follow-up time was 32.1 months. The median progression-free survival (PFS) was 9.4 months. Overall survival (OS) was 41.0 months, time to treatment failure (TTF) was 7.8 months, response rate (RR) was 31.3%, and disease control rate (DCR) was 78.1%. The incidence of grade 3 side-effects was not high.

CONCLUSION:

The 3-week schedule of S-1 can be considered useful as a treatment for patients with metastatic breast cancer, helping in maintaining a high quality of life.

• Authors: Mayuko Miki, Shintaro Takao, Muneharu Konishi, Yasushi Shigeoka, Masaru Miyashita, Hirofumi Suwa, Yasuo Miyoshi, Koichi Hirokaga, Toshitaka Okuno, Kazuhiko Yamagami, Michiko Imamura, Keiko Murase, Ayako Yanai, Hirokazu Tanino
• Journal: Anticancer research (Anticancer Res) Vol. 41 Issue 6 Pg. 3121-3126 (Jun 2021) ISSN: 1791-7530 [Electronic] Greece
• PMID: 34083305 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Antimetabolites, Antineoplastic
• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid

Topics

• Adult
• Aged
• Antimetabolites, Antineoplastic (administration & dosage, therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Drug Combinations
• Female
• Humans
• Middle Aged
• Neoplasm Metastasis (drug therapy)
• Neoplasm Recurrence, Local (etiology)
• Oxonic Acid (administration & dosage, therapeutic use)
• Tegafur (administration & dosage, therapeutic use)